BPHL Antibody

What is BPHL and what are its primary biological functions?

BPHL (biphenyl hydrolase-like) is a serine hydrolase enzyme that plays critical roles in several metabolic pathways. It primarily functions as a catalyst for the hydrolytic activation of amino acid ester prodrugs of nucleoside analogs such as valacyclovir and valganciclovir, converting valacyclovir to acyclovir . BPHL is also known as valacyclovir hydrolase (VACVASE) and may be involved in detoxification processes . It specifically functions as an alpha-amino acid ester hydrolase with preference for small, hydrophobic, and aromatic side chains, without stringent requirements for the leaving group beyond preferring primary alcohols .

What characterizes the substrate specificity of BPHL?

BPHL has a unique active site defined by a flexible and mostly hydrophobic acyl pocket, a localized negative electrostatic potential, and a large open leaving group-accommodating groove. The enzyme contains a pivotal acidic residue, Asp-123, located after the nucleophile Ser-122, whose side chain is directed into the substrate binding pocket, playing a critical role in the substrate discriminating ability of this serine hydrolase . This structure enables BPHL to effectively hydrolyze many amino acid ester nucleoside prodrugs while maintaining specificity for its substrates.

What types of BPHL antibodies are commercially available for research?

Most commercially available BPHL antibodies are polyclonal antibodies produced in rabbits. These antibodies are typically generated against human BPHL, though many show cross-reactivity with mouse and rat BPHL . The antibodies are generally provided in liquid form, in PBS buffer with sodium azide and glycerol, and are stored at -20°C . Most are unconjugated, though specific applications may require conjugated versions.

What are the validated applications for BPHL antibodies?

BPHL antibodies have been validated for several research applications, primarily Western blot (WB), immunohistochemistry (IHC), and enzyme-linked immunosorbent assay (ELISA) . Western blot applications typically detect BPHL at molecular weights between 27-32.5 kDa . For immunohistochemistry, BPHL antibodies have successfully detected the protein in human kidney, heart, lung, ovary, and placenta tissues . Additionally, positive Western blot results have been reported in human kidney tissue, human liver tissue, MCF-7 cells, and mouse kidney tissue .

What are the recommended dilutions and protocols for BPHL antibodies in Western blotting?

For Western blotting applications, BPHL antibodies are typically used at dilutions ranging from 1:500 to 1:2000 . The optimal dilution should be determined experimentally for each specific application and sample type. A general protocol involves:

• Denaturing tissue or cell lysate proteins at 40°C for 45 minutes

• Resolving proteins by 7.5% SDS-PAGE

• Transferring to a PVDF membrane

• Blocking with appropriate blocking buffer

• Incubating with primary BPHL antibody (1:500-1:2000) for one hour

• Washing three times with TBST

• Incubating with HRP-conjugated secondary antibody (1:1000-1:3000)

• Washing five times with TBST

• Developing with chemiluminescent substrate

How should BPHL antibodies be used in immunohistochemistry?

For immunohistochemistry applications, BPHL antibodies are typically used at dilutions ranging from 1:20 to 1:200 . Optimal results have been reported with antigen retrieval using TE buffer at pH 9.0, though citrate buffer at pH 6.0 may also be used as an alternative . Validated positive tissues include human kidney, heart, lung, ovary, and placenta tissues .

What controls should be included when using BPHL antibodies?

When designing experiments with BPHL antibodies, several controls should be considered:

• Positive controls: Include tissues or cell lines known to express BPHL, such as human kidney tissue, human liver tissue, or MCF-7 cells .

• Negative controls: BPHL knockout tissues or cells provide ideal negative controls . If unavailable, tissues known not to express BPHL can be used.

• Loading controls: Include appropriate loading controls such as β-actin for Western blot applications .

• Antibody controls: Include secondary antibody-only controls to assess non-specific binding.

• Peptide competition: For validation of antibody specificity, include controls where the antibody is pre-incubated with the immunizing peptide.

How can researchers validate the specificity of BPHL antibodies?

Validating antibody specificity is crucial for reliable experimental results. For BPHL antibodies, several approaches can be employed:

• Knockout validation: Compare antibody reactivity in wildtype versus Bphl knockout mice tissues .

• Multiple antibody validation: Use multiple antibodies targeting different epitopes of BPHL.

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding.

• RNA interference: Correlate protein detection with BPHL knockdown by siRNA or shRNA.

• Recombinant protein: Test antibody reactivity against purified recombinant BPHL protein.

What factors might affect experimental results when using BPHL antibodies?

Several factors may influence the performance of BPHL antibodies:

• Tissue fixation: Overfixation may mask epitopes, while underfixation may compromise tissue morphology.

• Antigen retrieval: Insufficient or excessive antigen retrieval can affect antibody binding.

• Antibody concentration: Too high or too low antibody concentrations can lead to non-specific binding or insufficient signal.

• Sample preparation: Improper sample preparation may denature or degrade BPHL.

• Cross-reactivity: Some BPHL antibodies may cross-react with similar proteins, especially in different species.

How can BPHL knockout models contribute to understanding drug metabolism?

BPHL knockout mouse models serve as valuable tools for investigating the role of BPHL in drug metabolism pathways. Studies have used Bphl knockout mice to evaluate the in situ intestinal permeability and stability of valacyclovir . These models allow researchers to:

• Assess the contribution of BPHL to prodrug activation in specific tissues

• Investigate compensatory mechanisms that may exist in the absence of BPHL

• Evaluate the pharmacokinetics of prodrugs that are BPHL substrates

• Identify potential off-target effects of drugs that interact with BPHL

• Develop more targeted prodrug strategies based on BPHL activity patterns

Protein levels of BPHL can be determined in various tissues (liver, jejunum, spleen, kidney) of wildtype and knockout mice through immunoblot analysis to confirm knockout status and assess potential changes in expression patterns of related enzymes .

What is known about tissue-specific expression of BPHL and how can antibodies help map this distribution?

BPHL expression varies across different tissues, with notable expression in kidney and liver tissues . BPHL antibodies have been instrumental in mapping this tissue distribution through immunohistochemistry and Western blot analysis. Positive immunohistochemical staining has been detected in human kidney, heart, lung, ovary, and placenta tissues . This tissue-specific expression pattern may correlate with the enzyme's role in drug metabolism and detoxification processes.

Researchers can use BPHL antibodies to:

• Compare expression levels across different tissues

• Identify cell-specific expression within heterogeneous tissues

• Investigate changes in expression during development or disease states

• Correlate expression patterns with prodrug activation efficiency

• Assess potential off-target effects of drugs targeting BPHL

How can BPHL antibodies be used to study drug resistance mechanisms?

Given BPHL's role in activating prodrugs like valacyclovir, alterations in BPHL expression or activity could potentially contribute to drug resistance. BPHL antibodies can be valuable tools in investigating such mechanisms:

• Expression analysis: Compare BPHL expression levels between drug-sensitive and drug-resistant cell lines or patient samples.

• Localization studies: Investigate whether changes in subcellular localization of BPHL correlate with drug resistance.

• Mutation detection: Combine with sequencing to correlate protein expression with genetic variants.

• Protein-protein interactions: Use in co-immunoprecipitation studies to identify potential interacting partners that may modulate BPHL activity.

• Post-translational modifications: Investigate whether post-translational modifications affect BPHL activity in drug-resistant contexts.

What are common technical issues when using BPHL antibodies and how can they be resolved?

When working with BPHL antibodies, researchers may encounter several technical challenges:

• Weak or no signal in Western blot:

  • Increase antibody concentration or incubation time

  • Optimize antigen retrieval method

  • Ensure proper transfer of proteins to membrane

  • Use fresh antibody solution

  • Check sample preparation protocol for protein degradation

• High background in immunohistochemistry:

  • Optimize blocking conditions

  • Reduce antibody concentration

  • Increase washing steps

  • Use more specific secondary antibody

  • Try different antigen retrieval methods

• Multiple bands in Western blot:

  • Optimize sample denaturation conditions

  • Use freshly prepared samples

  • Increase gel percentage for better resolution

  • Verify antibody specificity with knockout controls

  • Consider post-translational modifications or splice variants

How should researchers interpret unexpected molecular weight variations when detecting BPHL?

BPHL has a calculated molecular weight of 22-32.5 kDa, with an observed molecular weight of approximately 27 kDa . Variations from these expected values may result from:

• Post-translational modifications: Phosphorylation, glycosylation, or other modifications can alter protein migration.

• Splice variants: Alternative splicing may generate different isoforms with varying molecular weights.

• Sample preparation: Incomplete denaturation or sample degradation can affect migration patterns.

• Gel concentration: Different gel percentages may affect protein migration and apparent molecular weight.

• Species differences: BPHL from different species may have slightly different molecular weights.

When unexpected molecular weights are observed, researchers should:

• Compare with appropriate positive controls

• Verify with antibodies targeting different epitopes

• Consider known post-translational modifications

• Check literature for reported splice variants

• Validate with recombinant protein of known molecular weight

How can researchers integrate antibody-based detection with functional assays of BPHL activity?

To gain a comprehensive understanding of BPHL biology, researchers should combine antibody-based detection with functional assays:

• Correlation analysis: Compare BPHL protein levels detected by antibodies with enzymatic activity in the same samples.

• Activity assays following immunoprecipitation: Use BPHL antibodies to isolate the protein, then assess its enzymatic activity.

• Inhibitor studies: Correlate the effects of BPHL inhibitors on both protein detection and enzymatic activity.

• Expression systems: Overexpress BPHL in cell systems, then confirm both increased protein levels (by antibody detection) and enzymatic activity.

• Knockout/knockdown validation: Demonstrate both loss of antibody detection and enzymatic activity in knockout or knockdown models.